Anzeige
Mehr »
Login
Freitag, 04.10.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Citibank sagt $3.000 Gold voraus: Lernen Sie das Unternehmen kennen, das sich seit Jahren darauf vorbereitet
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40FP3 | ISIN: US8314454088 | Ticker-Symbol:
NASDAQ
03.10.24
21:59 Uhr
6,560 US-Dollar
-0,580
-8,12 %
Branche
Freizeitprodukte
Aktienmarkt
Sonstige
1-Jahres-Chart
CONNEXA SPORTS TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
CONNEXA SPORTS TECHNOLOGIES INC 5-Tage-Chart
GlobeNewswire (Europe)
289 Leser
Artikel bewerten:
(1)

Connexa Sports Technologies Inc.: Yuanyu Enterprise Management Co., Limited, Reports 1Q2024 Unaudited Financial Results

YYEM posts significant license revenue and net income increases
over prior year

Company, which is 20% owned by Connexa, to become
a subsidiary pending Nasdaq approval

Windsor Mills, MD, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Connexa Sports Technologies Inc. (Nasdaq: YYAI) reports unaudited operating results for the first quarter of FY24 from Yuanyu Enterprise Management Co., Ltd. ("YYEM"). Yuanyu is 20% owned by Connexa and will become a 70%-owned subsidiary of Connexa pending Nasdaq's approval.

"The strong financial results of YYEM for the first quarter of its financial year support the Board's decision to acquire a majority stake in the company, which the Board expects will deliver shareholder value and provide all Connexa shareholders with an opportunity to share in YYEM's success as it grows its operations in the 'love & marriage' industry," commented Mike Ballardie, Connexa CEO.

For the first quarter of YYEM's fiscal year, ended April 30, 2024, the Company reported revenue of $3.3 million, compared to $481,000 in the same three-month period a year prior, driven by payments from additional licensees signed up in 2023. $1.4 million of this revenue was derived from Southeast Asia, while $1.1 million was generated from the United States and $818,000 was generated from Europe. As a result, net income increased to $2.2 million, compared to $278,000 a year prior.

These financial results reflect the continuing development of YYEM as the Company works to redefine the future of matchmaking. They suggest that the YYEM business model and AI platform are resonating with the company's licensees and that the various businesses of YYEM are maturing and improving while gradually opening up the love & marriage market around the world. YYEM expects this growth to continue over the next few years as it becomes a leading brand within this sector.

YYEM operates in the emerging love & marriage market sector, where it owns significant proprietary intellectual property unique to this business sector, covering its licensees' online presence and underpinning their matchmaker operations. It owns six technologies related to the metaverse and five AI matchmaking patents, which together enable access to both Augmented Reality (AR) and Extended Reality (XR), enhancing its future revenue growth potential. YYEM's AI technology can also integrate with existing Big Data models and other larger AI models, such as Huawei Pangu 3, a feature designed to operationalize its AI and hone its technologies to create significant business value by helping its licensees deliver effective matchmaking services and helping their clients find successful life partnerships.

YUANYU ENTERPRISE MANAGEMENT CO., LIMITED
STATEMENTS OF OPERATIONS (IN USD)
THREE-MONTH PERIOD ENDED APRIL 30, 2024 AND 2023

For the three-month period ended
April 30,
2024 2023
Revenue $3,272,727 $480,769
Cost of revenue 744,231 144,231
Gross profit 2,528,496 336,538
Operating expenses
General and Administrative 34,120 4,169
Total operating expenses 34,120 4,169
Profit from Operations 2,494,376 332,369
Other Income / (Expense) - -
Total Other Income / (Expense) - -
Provisions for income taxes 321,572 54,841
Net income $2,172,804 $277,528

About Connexa Sports Technologies:

Connexa Sports is a leading connected sports company delivering products, technologies, and Sport-as-a-Service across a range of sport verticals. Connexa's mission is to reinvent sports through technological innovation driven by an unwavering focus on today's sports consumer.

About Yuanyu Enterprise Management Co., Limited

Yuanyu Enterprise Management Co., Limited (YYEM) operates across the rapidly emerging love & marriage sector. YYEM owns numerous patents, technologies, and algorithms that drive its big data and matchmaking analyses, deriving its current revenues from royalties. YYEM has multiple licensing agreements in place covering distinct regions around the world.

Contact Information:
investors@connexasports.com
www.connexasports.com

Forward-Looking Statements

Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements.

Actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in "Item 1A. Risk Factors" in our 10-K filing as of July 27, 2024 and our ability to continue as a going concern. Accordingly, you should not rely on these forward-looking statements, which speak only as of the date of this press release. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this press release.

In addition, statements such as "pending", "we believe", "expected" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this press release. And while we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly on these statements.

Although we believe the expectations reflected in the forward-looking statements were reasonable at the time made, we cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. You should carefully consider the cautionary statements contained or referred to in this section in connection with the forward-looking statements contained in this press release and any subsequent written or oral forward-looking statements that may be issued by us or persons acting on our behalf.


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.